MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
11.82
-0.32
-2.64%
After Hours: 11.75 -0.07 -0.58% 19:37 01/02 EST
OPEN
12.08
PREV CLOSE
12.14
HIGH
12.19
LOW
11.60
VOLUME
2.50M
TURNOVER
--
52 WEEK HIGH
16.44
52 WEEK LOW
5.79
MARKET CAP
2.52B
P/E (TTM)
-8.2295
1D
5D
1M
3M
1Y
5Y
1D
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales
Barchart · 19h ago
Weekly Report: what happened at OCUL last week (1222-1226)?
Weekly Report · 12/29/2025 10:25
Weekly Report: what happened at OCUL last week (1215-1219)?
Weekly Report · 12/22/2025 10:25
Interesting OCUL Put And Call Options For February 2026
NASDAQ · 12/19/2025 16:12
Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
TipRanks · 12/18/2025 22:11
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
TipRanks · 12/17/2025 11:45
Weekly Report: what happened at OCUL last week (1208-1212)?
Weekly Report · 12/15/2025 10:32
Healthcare Dashboard For December And Focus On PJP
Seeking Alpha · 12/14/2025 19:00
More
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.